TNK2 and prostate neoplasm: Combined with our previously published findings that show specific activation of ACK1 in prostate tumor cells (7, 27), these data demonstrate that methodical ACK1 squelching by (R)-9b leads to a loss of acK609-AR, resulting in a comprehensive response against CRPC.